vs
Side-by-side financial comparison of AerSale Corp (ASLE) and AVANOS MEDICAL, INC. (AVNS). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $90.9M, roughly 2.0× AerSale Corp). AerSale Corp runs the higher net margin — 5.9% vs -0.7%, a 6.7% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -4.0%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $9.8M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 0.2%).
AerSale, Inc. is a Doral, Florida-based global supplier of aftermarket commercial jet aircraft, engines, used materials, and aeronautical engineering services to passenger and cargo airlines, government, multinational original equipment manufacturers, and independent MROs. AerSale is a member of the Aircraft Fleet Recycling Association.
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
ASLE vs AVNS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $90.9M | $180.9M |
| Net Profit | $5.4M | $-1.3M |
| Gross Margin | 34.1% | 47.5% |
| Operating Margin | 7.8% | 1.4% |
| Net Margin | 5.9% | -0.7% |
| Revenue YoY | -4.0% | 0.7% |
| Net Profit YoY | 99.7% | 99.7% |
| EPS (diluted) | $0.10 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $90.9M | $180.9M | ||
| Q3 25 | $71.2M | $177.8M | ||
| Q2 25 | $107.4M | $175.0M | ||
| Q1 25 | $65.8M | $167.5M | ||
| Q4 24 | $94.7M | $179.6M | ||
| Q3 24 | $82.7M | $170.4M | ||
| Q2 24 | $77.1M | $171.7M | ||
| Q1 24 | $90.5M | $166.1M |
| Q4 25 | $5.4M | $-1.3M | ||
| Q3 25 | $-120.0K | $-1.4M | ||
| Q2 25 | $8.6M | $-76.8M | ||
| Q1 25 | $-5.3M | $6.6M | ||
| Q4 24 | $2.7M | $-397.3M | ||
| Q3 24 | $509.0K | $4.3M | ||
| Q2 24 | $-3.6M | $1.8M | ||
| Q1 24 | $6.3M | $-900.0K |
| Q4 25 | 34.1% | 47.5% | ||
| Q3 25 | 30.2% | 48.4% | ||
| Q2 25 | 32.9% | 52.6% | ||
| Q1 25 | 27.3% | 53.6% | ||
| Q4 24 | 31.4% | 54.6% | ||
| Q3 24 | 28.6% | 54.5% | ||
| Q2 24 | 28.2% | 55.7% | ||
| Q1 24 | 31.8% | 57.1% |
| Q4 25 | 7.8% | 1.4% | ||
| Q3 25 | 4.0% | 0.1% | ||
| Q2 25 | 11.7% | -42.6% | ||
| Q1 25 | -10.1% | 6.1% | ||
| Q4 24 | 5.2% | -233.0% | ||
| Q3 24 | 2.4% | 7.0% | ||
| Q2 24 | -2.4% | 3.7% | ||
| Q1 24 | 5.2% | 2.4% |
| Q4 25 | 5.9% | -0.7% | ||
| Q3 25 | -0.2% | -0.8% | ||
| Q2 25 | 8.0% | -43.9% | ||
| Q1 25 | -8.0% | 3.9% | ||
| Q4 24 | 2.9% | -221.2% | ||
| Q3 24 | 0.6% | 2.5% | ||
| Q2 24 | -4.7% | 1.0% | ||
| Q1 24 | 6.9% | -0.5% |
| Q4 25 | $0.10 | $-0.02 | ||
| Q3 25 | $0.00 | $-0.03 | ||
| Q2 25 | $0.18 | $-1.66 | ||
| Q1 25 | $-0.10 | $0.14 | ||
| Q4 24 | $0.05 | $-8.64 | ||
| Q3 24 | $0.01 | $0.09 | ||
| Q2 24 | $-0.07 | $0.04 | ||
| Q1 24 | $0.12 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.4M | $89.8M |
| Total DebtLower is stronger | $1.3M | $90.3M |
| Stockholders' EquityBook value | $424.4M | $778.2M |
| Total Assets | $640.5M | $1.1B |
| Debt / EquityLower = less leverage | 0.00× | 0.12× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.4M | $89.8M | ||
| Q3 25 | $5.3M | $70.5M | ||
| Q2 25 | $5.7M | $90.3M | ||
| Q1 25 | $4.7M | $97.0M | ||
| Q4 24 | $4.7M | $107.7M | ||
| Q3 24 | $9.8M | $89.0M | ||
| Q2 24 | $4.3M | $92.2M | ||
| Q1 24 | $2.6M | $75.8M |
| Q4 25 | $1.3M | $90.3M | ||
| Q3 25 | $1.5M | $93.4M | ||
| Q2 25 | $907.0K | $95.7M | ||
| Q1 25 | $1.1M | $98.0M | ||
| Q4 24 | $1.2M | $125.3M | ||
| Q3 24 | $376.0K | $152.6M | ||
| Q2 24 | $522.0K | $164.9M | ||
| Q1 24 | $3.5M | $167.2M |
| Q4 25 | $424.4M | $778.2M | ||
| Q3 25 | $417.1M | $778.0M | ||
| Q2 25 | $415.9M | $776.3M | ||
| Q1 25 | $406.5M | $839.4M | ||
| Q4 24 | $455.6M | $828.5M | ||
| Q3 24 | $451.5M | $1.2B | ||
| Q2 24 | $449.8M | $1.2B | ||
| Q1 24 | $452.0M | $1.2B |
| Q4 25 | $640.5M | $1.1B | ||
| Q3 25 | $646.3M | $1.1B | ||
| Q2 25 | $646.7M | $1.0B | ||
| Q1 25 | $646.1M | $1.1B | ||
| Q4 24 | $604.7M | $1.2B | ||
| Q3 24 | $601.5M | $1.7B | ||
| Q2 24 | $598.7M | $1.7B | ||
| Q1 24 | $571.7M | $1.7B |
| Q4 25 | 0.00× | 0.12× | ||
| Q3 25 | 0.00× | 0.12× | ||
| Q2 25 | 0.00× | 0.12× | ||
| Q1 25 | 0.00× | 0.12× | ||
| Q4 24 | 0.00× | 0.15× | ||
| Q3 24 | 0.00× | 0.12× | ||
| Q2 24 | 0.00× | 0.13× | ||
| Q1 24 | 0.01× | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.4M | $28.2M |
| Free Cash FlowOCF − Capex | $9.8M | $21.3M |
| FCF MarginFCF / Revenue | 10.8% | 11.8% |
| Capex IntensityCapex / Revenue | 1.7% | 3.8% |
| Cash ConversionOCF / Net Profit | 2.11× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-29.1M | $43.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.4M | $28.2M | ||
| Q3 25 | $-8.9M | $14.0M | ||
| Q2 25 | $19.8M | $6.8M | ||
| Q1 25 | $-45.2M | $25.7M | ||
| Q4 24 | $37.5M | $57.9M | ||
| Q3 24 | $10.4M | $23.0M | ||
| Q2 24 | $-15.3M | $27.8M | ||
| Q1 24 | $-21.5M | $-8.0M |
| Q4 25 | $9.8M | $21.3M | ||
| Q3 25 | $-9.8M | $7.0M | ||
| Q2 25 | $18.6M | $-4.2M | ||
| Q1 25 | $-47.6M | $19.0M | ||
| Q4 24 | $32.3M | $53.1M | ||
| Q3 24 | $8.9M | $20.0M | ||
| Q2 24 | $-18.9M | $21.9M | ||
| Q1 24 | $-25.0M | $-12.1M |
| Q4 25 | 10.8% | 11.8% | ||
| Q3 25 | -13.8% | 3.9% | ||
| Q2 25 | 17.3% | -2.4% | ||
| Q1 25 | -72.4% | 11.3% | ||
| Q4 24 | 34.0% | 29.6% | ||
| Q3 24 | 10.7% | 11.7% | ||
| Q2 24 | -24.6% | 12.8% | ||
| Q1 24 | -27.7% | -7.3% |
| Q4 25 | 1.7% | 3.8% | ||
| Q3 25 | 1.3% | 3.9% | ||
| Q2 25 | 1.1% | 6.3% | ||
| Q1 25 | 3.7% | 4.0% | ||
| Q4 24 | 5.6% | 2.7% | ||
| Q3 24 | 1.9% | 1.8% | ||
| Q2 24 | 4.7% | 3.4% | ||
| Q1 24 | 3.9% | 2.5% |
| Q4 25 | 2.11× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.31× | — | ||
| Q1 25 | — | 3.89× | ||
| Q4 24 | 13.89× | — | ||
| Q3 24 | 20.52× | 5.35× | ||
| Q2 24 | — | 15.44× | ||
| Q1 24 | -3.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASLE
| Products | $57.8M | 64% |
| Maintenance | $23.2M | 26% |
| Leasing Arrangements | $9.9M | 11% |
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
